Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 16.2% in November

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 8,620,000 shares, an increase of 16.2% from the November 15th total of 7,420,000 shares. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is presently 6.7 days. Approximately 10.9% of the shares of the stock are sold short.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors have recently bought and sold shares of CRBU. Barclays PLC increased its position in shares of Caribou Biosciences by 122.4% in the 3rd quarter. Barclays PLC now owns 129,839 shares of the company's stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. Geode Capital Management LLC boosted its stake in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company's stock valued at $3,980,000 after acquiring an additional 124,782 shares during the period. Erste Asset Management GmbH bought a new position in shares of Caribou Biosciences during the third quarter valued at approximately $28,000. PFM Health Sciences LP lifted its holdings in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company's stock worth $8,441,000 after purchasing an additional 223,299 shares during the last quarter. Finally, Walleye Capital LLC boosted its position in Caribou Biosciences by 45.9% during the 3rd quarter. Walleye Capital LLC now owns 237,599 shares of the company's stock valued at $466,000 after purchasing an additional 74,799 shares during the period. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Stock Performance

CRBU remained flat at $1.91 on Monday. The company had a trading volume of 1,297,024 shares, compared to its average volume of 1,699,327. Caribou Biosciences has a 1 year low of $1.50 and a 1 year high of $8.33. The stock has a market capitalization of $172.96 million, a P/E ratio of -1.16 and a beta of 2.27. The business has a fifty day moving average price of $2.09 and a 200-day moving average price of $2.03.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Research analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CRBU. Citigroup dropped their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, November 26th. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $10.20.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.